Home › Trial NCT06323525
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
- Trial IDNCT06323525
- StatusRecruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorChinese PLA General Hospital
- Enrollment30
- Start date2024-04-17
- ConditionsNon-hodgkin Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.